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ABSTRACT 
Exosomes are the extracellular vesicles surrounded by a phospholipid bilayer shed from all cell varieties and plays a significant role in the 
communication and Transportation of materials between the cells due to their ability to transfer the proteins and nucleic acids from One cell to the 
another cell. Analogous in size and performance to synthetic nanoparticles, exosomes provide several Advantages, rendering them the foremost 
promising candidates for targeted drug or gene delivery vehicles. This review highlights the isolation techniques and delivery potential of exosomes, 
and equally presents research or analysis gaps for enhancing the use of natural vesicles for delivery functions. Exosome-based drug formulations 
can be applied to an extensive variety of diseases such as various infectious, cardiovascular, cancer and neurodegenerative disorders. Mostly, 
exosomes combine the benefits of both synthetic nanocarriers and cell-mediated drug delivery systems however avoiding their limitations. 
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INTRODUCTION 
The term “exosome” was coined by Rose Johnstone in late 1970s, 
because the vesicles she found emerging from sheep reticulocytes 
structurally resembled endosomes, these particular ones were exiting 
material rather than entering [1]. Up to 1996 exosomes are regarded as 
the best waste-disposal vessels of cell homeostasis. This changed with 
the discovery of the B cells that can actually release functional antigen-
transferring exosomes. Hereafter the exosome scope has widened, over 
time attributing an array of the functionalities to these small 
extracellular entities. Cells can release multiple types of membrane 
vesicles, like plasma-membrane-budded microvesicles, multivesicular 
body-derived exosomes; Golgi apparatus-derived secretory vesicles or 
apoptotic bodies. All of these cell-derived microvesicles can carry 
biologically active cargo like proteins, mRNA and miRNA [2]. 
Structure of exosomes 
Exosomes are a class of round-shaped lipid bilayer vesicles with a 
diameter ranging from 30–150 nm, and in the image of exosomes 
EM, we can see that their shape is round-shaped and the distribution 
is monodisperse [3]. They are known to be associated with diverse 
pathological conditions and represent the variety of functions like 
delivering biomolecules and genetic material to recipient cells. 
Exosomes are enriched with the bundle of specific molecules which 
are different from proteins located in the plasma membrane 
including tetraspanins, heat-shock proteins, major 
histocompatibility molecules, cytoskeleton proteins (actin, tubulin, 
cofilin, myosin, vimentin, fibronectin, advillin, talin, CAP1, meosin, 
and keratin), microRNA (miRNA), messenger RNA (mRNA), 
Annexins (I, II, IV, V, VI, VII, and X1), apoptotic bodies [4]. 
Exosomes also contain a domain of lipids including sphingomyelin, 
ganglioside, ceramide and cholesterol called membrane rafts. There 
is an additional associated class of cytosolic proteins found in the 
exosomes includes Rabs, a family of GTPases involved in the 
vesicular transport and protein complexes that regulate the 
membrane fusion and docking. About 40 Rab proteins have been 
identified in the exosomes RAB27A, RAB27B, RAB11, and RAB35 [5, 
6]. Exosomes are special in their own way as they possess particular 
cell surface markers as a legacy from the cell of their origin. These 
cell surface markers provide exosomes the means of interaction with 
neighboring and distant cells [7, 8]. Possession of these potentials 
has made exosomes a very valuable therapeutic tool with inherent 
qualities in the biomedicine research area for targeted drug delivery 
to counter deadly diseases. In addition to proteins, lipids and mRNA, 
exosomes also transfer miRNA to recipient cells which can alter the 
pathologic genetic expression. 
 
 
Fig. 1: Structural components of the exosome. Exosomes are 
composed of a bundle of specific molecules including 
tetraspanins (CD9, CD63, CD81, CD82), HSPs (HSP60, HSP70, 
HSPA5, CCT2, and HSP90), MHCs (MHC-I and-II), cytoskeleton 
proteins (actin, tubulin, cofilin, myosin, vimentin, fibronectin, 
advillin, talin, CAP1, keratins, meosin), micro RNA and mRNA, 
Annexins I, II, IV, V, VI, VII and X1, and apoptotic bodies [8] 
 
Biogenesis, release, and uptake of exosomes 
The secretion of exosomes in the cells occurs by fusion of the Multi 
Vesicular Bodies (MVB’S) and the cell membranes most vibrant 
compartments which are actively involved in the internalization of 
extracellular ligands, post membranous invagination, and the release 
of different types of endocytic vesicles. Exosomes are formed by the 
inward budding of the endocytic vesicles and also contain 
cytoplasmic components. Continuous formation of the exosomes 
leads to the development of the MVBs. The membrane of MVBs is 
semipermeable and ensures that cargoes are selectively loaded into 
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these exosomes. Exosomes can have similar kinds of membrane 
constituents even if they have originated from different types of cells 
[9]. The preliminary steps involved in sorting out the proteins 
undergoing endocytosis are the inward budding processes on the 
cell surface, which can be the clathrin-dependent and independent 
ways. The endocytotic vesicles are then transferred to endosomes 
which have an internal acidic environment. The acidic pH gets 
reduced by some modification of protein composition in the late 
endosomes which gets shed into the endosomal lumen to form MVBs 
and further leads to the formation of the Intra Alluminal Vesicles 
(ILVs). MVBs are abundant in cholesterol which can have dire 
consequences for cell survival, so they get fused with the plasma 
membrane and release exosomes and MVBs with a low amount of 
cholesterol fuse with the lysosomes and are involved in the 
proteolysis. There are mainly two kinds of mechanisms involved in 
the formation of exosomes; ESCRT (endosomal sorting complexes 
required for transport) dependent (which comprises four proteins 
O, I, II, III, and lipid-dependent) and ESCRT independent. ESCRT-O 
separates ubiquitinated proteins, I and II complexes help in the 
budding, and III completes the process and leads to the formation of 
ILVs in the MVBs rich population. 
Exosomes primarily originate as ILVs then gets matured to MVEs 
[10, 11]. Tetraspanins such as the CD81, CD9, and CD63 play an 
important role in the composition of ESCRT-independent loading 
into the exosomes by organizing the membrane into Tetraspanin-
Enriched domains. The ESCRT complex mechanism, which is both 
dependent and independent, for packing of the protein cargo into 
exosomes is a sign of the existence of different MVB and exosome 
populations. Different types of cancerous cells secrete various types 
of exosomes which may vary in the morphology and miRNA 
composition [12, 13], but some secrete exosomes which get 
differentiated by these surface antigens having different protein 
content with various functions. The exosomes released from the 
apical and basolateral cell membranes may have the heterogeneous 
population of vesicles, but the existence of the controlled and 
specialized mechanisms control the selective, specific sorting of the 
protein and miRNA cargo into these vesicles. Numerous researchers 
explained about the biogenesis of exosomes, most of these 
mechanisms are still unclear. 
Isolation and purification of exosomes 
Isolation by differential ultracentrifugation 
This method has become the gold standard process for the 
isolation and purification of the exosomes and exosome-like 
particles mainly due to its simplicity and cost-effectiveness [14-
18]. This method relies on differences in density and size of the 
separated particles. The exosome source, mainly the biological 
fluids or plant juice, are subjected to the series of centrifugation 
process with increasing speeds and duration to eliminate the 
larger and higher-density components; the pellets which are 
derived from this step are discarded. The final round of 
centrifugation of the supernatant is carried out at a higher speed 
of about 100,000 × g to recover the pellet containing the 
exosomes, which is resuspended and washed in a buffer. This 
method is often modified for the different sources of the exosomes. 
For instance, for animal fluids (e. g., plasma), due to their viscosity, 
dilution of the fluid and centrifugation at increased speed and 
duration are necessary for obtaining high exosome yields. 
Differential ultra-centrifugation is the general process for exosome 
isolation and the resulting exosomes often contain contaminants, 
mainly nucleic acids and protein aggregates [19]. For further 
purification, an extra step can be added involving 30% sucrose 
gradient. Exosomes float on a sucrose gradient hence, this step is 
invaluable for obtaining pure exosomes. This process ensures that 
the majority of the contaminants isolated with the exosomes does 
not float with the exosomes and, thus, would be separated [20]. 
Isolation by ultrafiltration 
Due to the low purity of the exosomes isolated by differential 
ultracentrifugation, efforts have been made to devise methods for 
large-scale isolation of exosomes with both higher purity and yield. 
Ultrafiltration is a technique that separates biomolecules based on 
different sizes Lobb group [21] suggested this process as a faster 
alternative to ultracentrifugation when they observed that it led to a 
higher recovery of exosome particles. This method involves the use 
of membrane filters and pressure to eliminate large molecular size 
contaminants with subsequent isolation of exosomes. An emerging 
modification to this procedure involves the separation of the 
ultrafiltration product by liquid chromatography for further 
purification [22, 23]. This extra step is expected to increase the 
production cost, which is considered important when using 
exosomes in food applications. 
Isolation by immuno isolation 
In this process, antibodies coat the magnetic beads that target the 
proteins present on the exosome surface. This method relies on 
surface biomarkers that are differentially expressed on exosomes 
[14]. Although it ensures the isolation with higher purity, the major 
drawback of this process is the limited information available on the 
exosomal structures and surface compositions, especially for new 
plant sources. Besides, the process would not be efficient for large-
scale isolation of exosomes due to the dissociation and purification 
steps essential after their binding to the antibodies.  
  
 
Table 1: Identification and quantification methods 





 Sample is exposed to a monochromatic light and an 
appropriate detector detects the signal. To study 
the scattering of light from absorbing and non-
absorbing particles that are large compared to the 
wavelength of light by taking into consideration 
particle shape and the difference in refractive index 
between particles and the medium the particles are 
present in. 
1. Measurement of 
molecules with MW<1000 
Da. 
2. require low volume i.e. 2 
µl. 
DLS measurements are very 
sensitive to temperature and 
solvent viscosity. Hence the 
temperature must be kept 
constant and solvent 
viscosity must be known for a 






It is a ubiquitous requirement in a broad range of 
industry sectors. Product performance and stability 
depends on the ability to manufacture particle 
suspensions to fine tolerances without the presence 
of contaminants or aggregates. 
1. Single vesicles detection 
with a diameter of 50 nm. 
Exosomes preparation is only 
semi-quantification and 
considerable intra-assay 





The energy of photons can be used for many useful 
chemical reactions, including solar production of 
fuels and water purification. While these 
photocatalytic processes are potentially very useful 
and their efficiency is far too low for practical large 
scale applications. 
1. Require small 
sample volumes and 
competence of total mass 
of exosomes, including 
proteins, lipids and 
nucleotides. 
Quality control is inadequate 
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Exosome characterization  
The characterization of exosomes can be summarized by its size, 
protein and lipid content. Generally, they can be identified by detecting 
the morphology, particle size, and surface markers on the surface of 
exosomes. Methods like transmission electron microscopy (TEM), 
scanning electron microscopy (SEM), cryo-electron microscopy and 
atomic force microscopy (AFM) are commonly employed to 
characterize the microstructure of exosomes. Nanoparticle tracking 
analysis (NTA) and dynamic light scattering (DLS) are two attractive 
techniques for measuring the distribution of particles in suspension. 
NTA is an optical particle tracking technique developed rapidly to real-
time monitor the size distribution and concentration of particles. The 
concentrations of exosomes and vesicles were determined from 
biological fluids by surface plasmon resonance (SPR). Some of the 
identification methods were summarised in table 1. 
Preparation of exosomes and exosome-mimetics 
Drug loading methodologies 
The drug loading methodologies applied to date in the case of 
exosomes, and their physical mimetics (Cellular vesicles), are 
categorized into two main groups, the pre-loading methods and the 
post-loading methods. 
In pre-loading methods, the drug is initially produced or loaded in 
the parental cells, and therefore, the extracellular vesicles or cellular 
vesicles isolated or produced by them are previously pre-loaded 
with the desired drug. Such methodologies are predominantly useful 
when oligonucleotides or proteins are to be loaded in the vesicles, in 
which case the cells can be programmed to produce “a-la-carte” 
extracellular vesicles or cellular vesicles.  
In post-loading methods, the drug is loaded in the extracellular 
vesicles after their separation. Though, we have not been able to 
notice any reports regarding the potential to use superior loading 
methods that have been very successful for effective loading of 
amphiphilic drugs into liposomes, such as the “active or remote” 
loading approaches for amphiphilic drugs, such as Doxorubicin etc, 
which can be established as a “one-stop” manufacturing methods on 
a microfluidic setup, as recently proven [24, 25]. 
Preloading methods 
Treatment of parental cells with drugs 
In this technique, the parental cells are treated with a drug, and the 
cells then secrete drug-pre-loaded exosomes or extracellular 
vesicles. Although it is impossible to regulate the loading efficiency 
with this type of methods, several studies, which are summarized 
below, have been conducted using such techniques, owing to their 
simplicity. Encapsulated paclitaxel (PTX) into murine SR4987 
mesenchymal stroma cells after culturing the cells with a low dose of 
PTX for 24 h, and then, washing and reseeding them with fresh 
medium. After 48 h, PTX-loaded-exosomes primed with high dose of 
PTX were collected. The PTX-loaded exosomes presented strong 
anti-proliferative activity against CFPAC-1 human pancreatic cells, as 
associated with control exosomes which were isolated from 
untreated cells [21]. 
Isolated extracellular vesicles from resistant hepatocellular 
carcinoma cells (HepG2) cells treated with different drugs 
(carboplatin paclitaxel, etoposide and irinotecan hydrochloride) 
were isolated. After exposure to the anticancer drugs, membrane 
microvesicles established by TEM and Western Blot to be exosomes 
were actively released by the cells. The later exosomes differed in 
their capability to present heat shock proteins (HSPs) on the cell 
surface. Their size ranged between 30 and 100 nm with the bulk of 
the vesicles being around 70–90 nm [22]. Synthetic fusogenic 
liposomes which were loaded with hydrophobic drugs were 
efficiently incorporated into the host cell membrane and the drugs 
were subsequently loaded into the membranes of the cell-secreted 
extracellular vesicles [27]. The same group used this method to 
introduce lipid-azides in the membrane of extracellular vesicles 
which were extra conjugated with targeting moieties and loaded 
with Paclitaxel (PTX) and tirapazamine (TPZ) [28]. 
Parental cell engineering 
In the last decade, an increasing number of reports in the literature 
define methods for successful loading of therapeutic cargo in 
exosomes, by modulation of the exosome-producing parental cells. 
The most common cell engineering techniques include transfection 
or activation of parental cells. 
Transfection is the most widely used and effective method for the 
loading of therapeutic proteins or oligonucleotides into exosomes. 
RNA (miRNA, siRNA, and mRNA) and protein sequences are simply 
transfected as synthetic oligonucleotides or expressed from a 
plasmid backbone. Cell transfections are carried out by the calcium 
phosphate method or by commercially available lipid transfection 
components such as lipofectamine, or others. With such approaches, 
biological cargos can be packaged into exosomes to promote or 
silence gene expression or regulate transcription in recipient cells. 
Studies have revealed that transfection can also be used to 
overexpress a specific protein on the surface membrane of the 
exosomes, or the proteins could be packaged into the exosome 
lumen. Certainly, in addition to modifying exosome membranes 
through genetic engineering of their parent cell, the therapeutic 
cargo of exosomes may also be manipulated by altering various 
aspects of their regulated biogenesis. 
miRNAs were effectively introduced into exosomes in several 
studies by using miRNA expression vectors. Transfecting modified 
miR-143 in THP-1 macrophage cells led to the successful loading of 
the modified miRNA into the exosomes are presented and this work 
showed that when overexpressing a miRNA into parental cells, this 
effectively leads to the passive load of miRNA into exosomes [24]. 
The miRNA-loaded exosomes can also be targeted efficiently to 
recipient cells after engineering their surface with targeting 
peptides, and proven that intravenously injected exosomes 
accumulated in the tumor site and reduced the tumor growth [25]. 
Interestingly, cell activation has been used as a method for loading 
functional cargo into exosomes. Though it is not the most suitable 
method for exosome loading, it shed light on some characteristics of the 
physiology and function of exosomes. Cell activation as a methodology 
for exosome loading was, though, only studied a few times.  
Post-loading methods 
In this section, the post-loading methods which have been used to 
date for drug loading into engineered exosomes of artificial-
exosomes are defined, starting from the simplest methods and 
continuing with the most complex ones (usually applied in liposome 
technology). 
Incubation with drug 
The simplest way to incorporate any cargo into exosomes is their co-
incubation, merely by mixing the isolated vesicles with the drug. The 
driving force for the loading is the altered concentration of the drug 
in and out of the vesicle membrane. The low loading capacity is 
considered as the main disadvantage of this method. The loading 
efficiency of co-incubation process depends on the lipophilic 
properties of the drug, as well as the concentration gradient [32]. 
Certain examples of drug loading into exosomes by their incubation 
with the drug of interest are given below:  
Incubation of curcumin with exosomes in PBS at 22 °C for 5 min and 
the exosomes were later purified [26]. Curcumin was hence self-
assembled into the lipid bilayer of exosomes over hydroscopic 
interactions, resulting in improved drug stability. Using the similar 
method, Encapsulation both curcumin (Exo-Cur) and a signal 
transducer and activator of transcription 3 (Stat3) inhibitor (Exo-
JSI124), by mixing curcumin or JSI124 with EL-4 cell-derived 
exosomes in PBS. Drug-loaded exosomes (Exo-cur or Exo-JSI124) 
were subsequently separated after incubating at 22 °C for 5 min. 
Recognition of an efficient, robust and highly-reproducible 
technique for loading therapeutic RNA into exosomes upon co-
incubation of hydrophobically altered small interfering RNAs 
(hsiRNAs) and exosomes, without affecting both the vesicle size and 
their integrity [27]. Loading of porphyrins of different 
hydrophobicities into exosomes by incubation with the drug at RT 
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for 10 min and effective loading of the enzyme catalase (a tetramer 
protein of 250 kDa) into RAW264.7 cell-extracted exosomes in PBS 
at RT for 18 h [28]. 
Electroporation 
By this technique, an electrical field distracts the phospholipid 
bilayer of vesicles (such as extracellular vesicles or exosomes or 
cells), making small pores in their membrane, and therefore 
allowing the passage of the drug into the vesicles. The integrity of 
the vesicle membrane is then recovered, causing the development of 
drug-loaded vesicles [30]. 
Electroporation was performed at 200 Ω, 500 μF, 200 mV and a 
pulse time of 20–30 ms [35]. Further examples of drug loading into 
exosomes by electroporation include DOX loading into mouse 
immature dendritic cells (engineered to express Lamp2b (an 
exosomal membrane protein) fused to αv integrin-specific iRGD 
peptide (CRGDKGPDC)) derived exosomes. The purified exosomes 
were capably loaded with DOX via electroporation. 
Sonication 
In this process, exosomes derived from donor cells are mixed with 
drugs and subsequently sonicated by a probe sonicator which allows 
the drug to flow into the exosomes due to the sonication-induced 
deformation of their membrane. In principle, the reformation of 
exosomal membranes under sonication may allow the passage of 
drugs across relatively tight lipid bilayers [37]. Specific examples of 
drug loading with sonication are presented below:  
Sonication is a method to load paclitaxel (PTX) into macrophage-
released exosomes; the method resulted in great loading efficiency and 
sustained drug release, while it did not significantly affect the protein or 
the lipid contents of the exosomes [31]. Sonication was also used as a 
process to load small RNAs (siRNA and miRNA) into exosomes (and 
microvesicles). However, the application of exosomes for therapeutic 
RNA delivery may be inadequate by such loading approaches that may 
induce cargo aggregation or degradation. Functional small RNAs (siRNA, 
miRNA or single-stranded DNA (ssDNA)) into exosomes isolated from 
two altered cell lines were loaded, HEK293T and MCF-7 by sonication. 
For this, the nucleic acids were incubated with the exosomes at RT for 30 
min and sonicated in a bath sonicator at 35 kHz for 30 s. Then the 
Mixtures were placed on ice for 1 min and sonicated again for the same 
time period. These conditions led to minimal detectable aggregation 
probably because of the minor sonication conditions applied [32]. 
Extrusion 
In this process, exosomes are mixed with a drug, and the mixture is 
loaded into a syringe-based lipid extruder and extruded through 
membranes with 100–400 nm porous size, at controlled 
temperature. During the extrusion, the exosome membrane is 
interrupted and vigorously mixed with the drug, resulting in drug 
loading into the exosomes.  
Loaded porphyrins of altered hydrophobicities into exosomes by 
extrusion were loaded. The procedure was carried out at 42 °C using a 
syringe-based, hand-held mini-extruder equipped with a heating block, 
and polycarbonate membranes of 400 nm pore size. Each sample was 
extruded 31 times. It was found that the extrusion method caused in 
alteration of the zeta potential of the vesicles, due to modulation of the 
constitution of the lipid membrane of original exosomes. The extruded 
exosomes were demonstrated to cause cytotoxicity, whereas exosomes 
loaded with similar porphyrin but prepared by other methods did not 
show significant cytotoxicity. Catalase has similarly been loaded into 
RAW264.7 macrophage-derived exosomes by extrusion. The catalase-
exosome mixture was efficiently extruded (×10 times) through 200 nm-
pore diameter filters [28]. 
Freeze/thaw cycle method 
In this process, drugs are mixed and incubated with exosomes at RT, 
and the mixture is then frozen at −80  °C or in liquid nitrogen, and re-
thawed at RT. This process is repeated for at least 3 cycles to 
safeguard drug encapsulation [42]. However, by this method 
exosomes, may aggregate, while the drug loading efficiency is 
usually lower than that of sonication or extrusion. 
The freeze-thaw technique has been used for catalase incorporation 
into exosomes. The catalase solution was mixed with the exosomes, 
freezed at −80  °C, incubated for 30 min and thawed at RT. The 
freeze-thaw cycle was repeated for three times [36]. 
A new approach to formulate engineered hybrid exosomes by fusing 
the membranes of exosomes with those of liposomes, using a freeze-
thaw method for this is proposed and Raw 264.7 cell-derived 
exosomes were mixed with fluorescently-labeled liposomes composed 
of phospholipids, pegylated-phospholipids, and fluorescently labelled 
phospholipids. These mixtures were frozen in liquid nitrogen and 
thawed at RT for 15 min. To examine the applicability of the 
membrane fusion technique, they investigated the fusion behavior 
between exosomes bearing a specific membrane protein (HER2) and 
liposomes. HER2 and phosphorylated HER2 were detected in the 
exosome-liposome mixtures, representing that exosome-liposome 
hybrids carrying specific proteins can be obtained by freeze-thaw 
methods. Cellular uptake studies performed using the hybrid 
exosomes shown that the interactions between the developed 
exosomes and cells can be changed by varying the lipid composition, 
and consequently, also the properties of liposomes [33]. 
Saponin-assisted loading 
Saponin is named from the Latin “sapo” which means “soap”; it is a 
surfactant molecule that, upon incubation with exosomes, produces 
pores in their membrane through interactions with cholesterol, 
leading to increased exosomes-membrane permeability. The sugar 
chain can contain from one to numerous monosaccharide residues, 
and is usually attached at C-3. The surface activity, as well as some 
additional biological functions of saponins (including their 
haemolytic activity), are attributed to their characteristic structural 
features and their amphiphilic nature which is are the results of the 
presence of a hydrophilic sugar moiety and a hydrophobic genin 
(called sapogenin) [34]. 
Catalase into exosomes ex vivo using different methods were loaded 
by the saponin-assisted process, a mixture of catalase and exosomes 
was supplemented with 0.2% saponin and placed on a shaker for 20 
min at RT. This technique caused in high loading efficiency sustained 
release, and catalase preservation against proteases degradation. 
Although saponin is a surface-active agent, it did not degrade 
catalase, whose activity was preserved [29]. 
Saponin can also help in loading other hydrophilic molecules into 
exosomes. For saponin-assisted drug loading of hydrophilic 
porphyrins, exosomes and the drug were incubated with 0.1 mg/ml 
saponin at RT for 10 min and high drug loading was assessed by this 
method [35]. 
Though, there are concerns regarding the in vivo haemolytic activity of 
saponin. Haemolysis of red blood cells seems to result from the 
capability of saponin to form complexes with the cholesterol of the cell 
membrane, leading to the development of pores, cell membrane 
permeabilization, and alterations in the negatively-charged 
carbohydrate portions on the cell surface. In any circumstance, when 
used as a method to assist drug-loading into exosomes, the concentration 
of saponin should be kept to a minimum, and the exosomes should be 
washed instantly after incubation with saponin [39]. 
Applications of exosomes in the pathogenesis, diagnostics, and 
therapeutics 
Exosomes show a wide variety of functions in the cell including cell 
communication, diagnostic markers, and potential roles in 
therapeutics. Modern studies demonstrated the possible role of 
exosomes as a biomarker for early diagnosis of diseases [40, 41]. In 
the past few years more attention has been focused on the role of 
exosomes in the pathophysiology of a variety of diseases including 
metabolic disorders, cancer, cardiovascular diseases, immune 
diseases, and neurodegenerative diseases. 
Exosomes in inflammatory diseases 
Exosomes are known to play a vital role in treating a variety of 
autoimmune diseases and inflammatory reactions as potential 
therapeutic agents. On the other hand, exosomes released from 
infected cells demonstrate a variety of functions. Further, the 
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exosomes released from pathogen-stimulated brain cells have 
miRNAs which could interfere with the gene expression of different 
other cells [42]. In asthmatic patients, the release of exosomes from 
the bronchial epithelial cells in the lungs is enhanced and might be 
responsible for the enhancement in intercellular signalling. 
Exosomes those are released from the epithelial cells which are 
treated with the interleukins 13 (IL-13) stimulate the inflammation 
along with cell proliferation, but some specific drugs that result in 
the inhibition of exosomes production can lead to diminishing the 
inflammation [43]. 
Exosomes from Mycobacterium tuberculosis-infected macrophages 
contain mycobacteria-derived antigens and cause the induction of 
inflammatory immune responses while inhibiting IFN-γ dependent 
activation of the macrophages [44, 45]. In the same way, exosomes 
released from Mycobacterium avium or Mycobacterium smegmatis 
infected macrophages have great Hsp70 expression; though, the 
stimulation of the nuclear factor kappa-light-chain-enhancer of 
activated B-cells (NF-κB) pathway helps producing high levels of the 
tumor necrosis factor-α (TNF-α)[37,38]. Exosomes with Hsp70 
expression could produce a pro-inflammatory response with the 
release of TNF-κB by macrophages and promotion of NK cell activity 
[46]. The Curcumin-loaded exosomes are used to activate myeloid 
cells, which are involved in the control and development of 
autoimmune diseases associated with inflammation (EL-4) [32]. 
Exosomal curcumin helps in the decrease of the number of 
CD11b1Gr-11 cells which are responsible for causing acute lung 
inflammation by increasing the solubility, stability, and 
bioavailability of curcumin after encapsulation into the lipid bilayer 
of the exosomes. Nevertheless, it becomes easier to deliver the 
encapsulated curcumin to the brain via intranasal administration. 
Earlier studies have exhibited that exosomes those are secreted 
from cancerous cells release certain cytokines into the 
microenvironment which are recognised with triggering of the 
immune response against tumorigenic tissue [47, 48]. On the 
contrary, exosomes that are derived from tumor tissue demonstrate 
exactly the opposite immune response in a manner of bearing 
different immunosuppressive molecules. This happens either 
because of decline in CD41, CD81, and natural killer cell stimulation 
or amplification in the differentiation of the immunosuppressive 
cells [5]. Injecting of exosomes obtained from tumor cells helps in 
supporting metastasis by decreasing natural killer cells activation, 
but increased the differentiation of myeloid cells and lead to the 
development of melanoma and carcinoma [49]. Till date, there are 
no relevant explanations given for these controversial results by 
different scientists, but it could be speculated to be due to the 
heterogeneous population of exosomes. 
Exosomes in cancer 
Cancer is the foremost cause of mortality worldwide. Existing 
treatment methods include surgery, chemotherapy, and radiation 
which further raises toxicity concerns. Since these methods are 
unable to cure metastasis of the cancerous cells there is an excessive 
need to develop more effective and less toxic therapies. 
Immunotherapy is a much-explored way of treating many types of 
cancers. Antibodies have presented a clinical accomplishment for 
cancer immunotherapy as well [38]. Latest research reports show 
the potential role of exosomes in cancer treatment as well as 
diagnosis and prognosis [50-55]. The RNA and proteins content from 
tumor-derived exosomes are involved in disseminating malignancy 
to recipient cells. This provides diagnostic information and aid in 
therapeutic selection for cancer patients. The most significant fact 
about exosomes is their ability to stimulate the immune response 
that can be exploited for the development of cancer vaccines [56]. 
Exosomes in neurodegenerative diseases 
Exosomes are involved in a variety of neurological disorders 
including Alzheimer’s disease (AD) and Parkinson’s disease (PD). 
They are released by numerous cell types like normal or pathogenic, 
into the extracellular environment. Mostly, exosomes released by 
tumor tissues initiate the metastasis and highlight the fact that 
exosomes have the ability to spread diseases within the body [57]. 
This ability of exosomes to spread the diseases is measured to be 
responsible for neurodegenerative disorders. Although the accurate 
mechanism of transmission is yet to be discovered, numerous 
studies have revealed that it could be either by cell to cell 
communication or via tunneling nanotubes [58,59]. Various research 
studies have demonstrated the involvement of exosomes in the 
transmission as neurodegenerative proteins were found to be 
secreted from the cell in association with exosomes. Due to their 
small size and relative stability, exosomes can cross the blood-brain 
barrier (BBB) therefore, reveal bright perspectives toward diagnosis 
and as therapeutic tools for future neuro medicine [58]. 
Exosomes as nanocarriers 
Nanoparticle drug delivery systems deliver many benefits like their 
ability to load high quantities ability to load both drug along with the 
adjuvant for the introduction of costimulation within a specific 
nanocarrier, sustained release of the loaded drug. Different types of 
nanocarriers have been considered at length for the targeted drug 
delivery of drugs or genes to a specific site of cancerous tissue. 
Nanocarriers are most-exploited in this field because they are more 
permeable along with the ability to accumulate into tumors 
passively as well as having the competence of longer retention, for 
example, DCs. Macrophages and primary cells are the natural 
phagocytotic involved in antitumor immunity and inflammatory 
response hence, Nano-drug delivery systems are the promising 
platforms in delivering immunomodulatory compounds to these cell. 
Exosomes, also called biological nanocarriers, are becoming visible 
as a promising alternative to this new theory of drug delivery [59]. 
Drug delivery vehicles for nucleic acids 
Exosomes are exceptionally outstanding delivery systems which can 
also carry DNA and RNA-like big and heavy molecules to the target 
cells, thus instigating genetic modification in the biological 
processes. This approach can be employed as a promising tool for 
delivering genetic material and altering the gene expression in 
certain diseases and help progress gene therapy. 
Delivery application of exosomes 
Exosomes expanded a lot of interest over the past decade because of 
their potential as a Nano delivery system, and advantages over other 
delivery systems. For instance, exosome vesicles form innately and 
naturally contribute as nanocarriers. Exosomes also have a target 
ability benefit as they bind specific targets due to their unique surface 
compositions. On reaching their destination, exosomes can discharge 
their contents into the target cells through either phagocytosis or 
membrane fusion [60]. Although exosomes generally have a natural 
targeting capability, which differs depending on their source, their 
preferred target can be customized by inserting molecules in donor 
cells (sources) that would be recognized by the recipient cells in the 
body. This method includes inserting genes that code for proteins that 
target specific cells so that exosomes secreted from those cells possess 
the desired targeting capability. 
Mammalian exosomes as a delivery 
Vehicle for nutraceutical compounds in planning a drug delivery 
system for Parkinson’s disease [36], specified the efficient 
encapsulation and stabilization of catalase with exosomes isolated 
from murine monocytes and macrophages. A size range of 100–200 
nm was obtained for the catalase-loaded exosomes, which had a high 
loading efficiency, sustained release, its content preserved from 
degradation by proteases, and important in vitro and in vivo 
neuroprotective properties. In one study, exosome encapsulation 
enriched the bioavailability and anti-inflammatory activity of 
curcumin and ensured target specificity toward inflammatory cells 
[32]. The attention providing to animal-derived exosomes as 
delivery vehicles for bioactive compounds is because of their 
biocompatibility, biorecognition, target specificity, and stability. 
Delivery of bioactive plant components 
Exosome-like particles derived from plants have recently extended a 
lot of interest. The vesicles, situated in the paramural space of plants, 
are associated in structure and function to their mammalian 
counterparts and are recognised as plant-derived edible 
nanoparticles (PDENs). Majority of the plant sources have 
characteristic and unique compounds with physiologically relevant 
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bioactivities. It is probable that the bioactive compounds are also 
delivered to their targets via exosome-like vesicles. It was reported 
that ginger-derived exosomes possess high levels of phosphatidic 
acid, which promotes intravesicular fusion for target delivery; there 
would be a necessity to offload the inherent bioactive compounds in 
exosomes in order to reach a great loading efficiency with the 
bioactive compounds of interest. 
Research studies of exosomes as drug delivery systems 
Exosomes are 30–100 nm nanoparticles secreted by cells into the 
extracellular environment. The possibility of nanoparticle exosomes as 
a carrier to entrap curcumin, curcumin was mixed with exosomes and 
then subjected to sucrose gradient centrifugation Exosomal protein 
markers, such as TSG101 and CD81 were identified in the exosomal 
curcumin [61]. Recently, exosomes have been employed to deliver 
exogenous nucleic acid drugs to specific cell types or tissues in vivo 
especially tumor tissues and they have shown great promise as 
naturally occurring nano-sized drug carriers. First example of using 
exosomes is for the targeted delivery of the chemotherapeutic drug 
Doxorubicin to solid tumors. Systemic administration of Doxorubicin 
delivery system significantly inhibited tumor growth causing no over 
toxicity. Studies suggest that exosomes appear to be superior candidates 
for specifically transporting therapeutic drugs to tumors resulting in 
significant inhibition of tumor growth [62]. Fluorescent doxorubicin and 
paclitaxel alone are formulated with bEND3 exosomes were prepared 
and penetration into brain tissue was evaluated. When given alone, the 
images showed no distribution of fluorescent drug out of the vasculature 
and into the brain. However, when formulated with exosomes both 
drugs are distributed into the brain region. These results indicate that 
exosomes can effectively deliver the anticancer drugs across the BBB 
into the brain in vivo [63]. Exogenous siRNAs were successfully 
introduced into various kinds of human exosomes and were used to 
deliver siRNA to human mononuclear blood cells. Plasma exosomes 
effectively delivered the siRNA into the target cells [66, 67]. Some of the 
research studies conducted using exosomes as drug delivery systems 
were summarized in table 2. 
 
Table 2: Summary of studies conducted using exosomes as drug delivery systems 
Research  Aim  References 
 Small molecules Using exosomes to improve the delivery of curcumin  [61] 
Delivery of doxorubicin into tumor tissue  [62]  
Deliver paclitaxel and doxorubicin across blood-brain barrier  [63] 
Protein Deliver catalase across BBB to treat PD  [64] 
siRNA 
 
Human exosomes to deliver siRNA into T cells [65] 
Exosomes to deliver siRNA into HeLa and Fibrosarcoma cell line (HT1080 cells)  [66] 
Delivery of siRNA using endothelial-derived exosomes  [67] 
 miRNA Exosome to antitumor miRNA into breast cancer cells  [25, 67] 
 
Advantages and disadvantages 
A proportion of drug compounds in the in vivo conditions are very 
unstable and have many challenges like drug resistance, low access 
to target tissue and so on for successful treatment. On the other 
hand, because of the problems associated with many drug delivery 
systems such as cytotoxicity of organic and non-organic 
nanoparticles, the improvement of delivery systems based on 
biological patterns is very important. Because of the negligible size 
of the exosomes between 30–150 nm along with their 
biocompatibility and hydrophilicity, and cheapness compared to 
nanomaterials, this vehicle can progress the constancy of drugs by 
loading the drug in the interior space and even on its outer surfaces 
through preventing macrophage phagocytosis. While exosomes also 
increase the cellular uptake in drug resistance by cancer cells. 
However, the lack of a complete understanding of the nature of 
exosomes due to their heterogeneity caused from undesirable 
separation and lack of purity in production, as well as the possibility 
of exacerbation of the disease due to the presence of exosomes that 
have the same activity as metastatic cancer exosomes, has been 
confronted with uncertainties and fear in clinical practices. 
Challenges of exosome-based nanocarriers for drug delivery 
The major drawback with the use of exosomes as a delivery agent is 
centered on the isolation process, inefficient extraction, low extraction 
yield, low encapsulation and loading efficiencies, and issues with 
delivery of exogenous hydrophilic macromolecules, and potential 
delivery of undesired cargo materials naturally present in the 
exosomes. Maximum exosome extraction methods are complex, labor-
intensive, and give low yield. However, recent extraction and detection 
techniques have shown promise, such as magnetic adhesion and flow 
cytometry in addition to better loading techniques such as sonication 
[38], electroporation and incubation. However, offloading the content 
of the exosome without distorting the structural integrity is very 
substantial in ensuring high loading and encapsulation efficiencies. 
Finally, there is a necessity for exosome functionalization to 
accommodate the encapsulation of exogenous hydrophilic 
macromolecules both by pre-formation (i.e., during exosome 
biogenesis) or post-formation loading (i.e., after exosome isolation). 
CONCLUSION 
Exosomes are nanosized vesicles secreted by a range of variety of cells 
and have ideal features as nanocarriers for drug and gene delivery. 
Exosomes are well-known to be associated with diverse pathologies 
and represent a variety of functions like delivering biomolecules such 
as mRNAs, miRNAs, siRNA, drugs and proteins to the recipient cells by 
communication at intercellular and tissue levels. Exosomes show a 
wide variety of functions in the cell including, diagnostic markers, and 
their potential role in therapeutics. Certain exosomes comprise of 
immunostimulatory or immunosuppressive effects which can be used 
as immunotherapies for cancer or autoimmune diseases. Emerging 
evidence has discovered the promising therapeutic potential of 
exosomes as effective nano-vaccines and immunological treatment for 
inflammatory diseases. Further investigation is required to fully 
elucidate the use of exosomes in diagnostic and therapeutic measures. 
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